183 related articles for article (PubMed ID: 8800626)
1. A risk-benefit assessment of sulpiride in the treatment of schizophrenia.
Mauri MC; Bravin S; Bitetto A; Rudelli R; Invernizzi G
Drug Saf; 1996 May; 14(5):288-98. PubMed ID: 8800626
[TBL] [Abstract][Full Text] [Related]
2. Spotlight on amisulpride in schizophrenia.
Curran MP; Perry CM
CNS Drugs; 2002; 16(3):207-11. PubMed ID: 11888341
[TBL] [Abstract][Full Text] [Related]
3. Amisulpride: a review of its use in the management of schizophrenia.
Curran MP; Perry CM
Drugs; 2001; 61(14):2123-50. PubMed ID: 11735643
[TBL] [Abstract][Full Text] [Related]
4. Aripiprazole: a review of its use in schizophrenia and schizoaffective disorder.
Swainston Harrison T; Perry CM
Drugs; 2004; 64(15):1715-36. PubMed ID: 15257633
[TBL] [Abstract][Full Text] [Related]
5. Quetiapine : A Review of its Use in Schizophrenia.
Gunasekara NS; Spencer CM
CNS Drugs; 1998 Apr; 9(4):325-40. PubMed ID: 27521016
[TBL] [Abstract][Full Text] [Related]
6. Amisulpride: a review of its use in the management of schizophrenia.
McKeage K; Plosker GL
CNS Drugs; 2004; 18(13):933-56. PubMed ID: 15521794
[TBL] [Abstract][Full Text] [Related]
7. Upcoming agents for the treatment of schizophrenia: mechanism of action, efficacy and tolerability.
Bishara D; Taylor D
Drugs; 2008; 68(16):2269-92. PubMed ID: 18973393
[TBL] [Abstract][Full Text] [Related]
8. Positron emission tomography measurement of dopamine D₂ receptor occupancy in the pituitary and cerebral cortex: relation to antipsychotic-induced hyperprolactinemia.
Arakawa R; Okumura M; Ito H; Takano A; Takahashi H; Takano H; Maeda J; Okubo Y; Suhara T
J Clin Psychiatry; 2010 Sep; 71(9):1131-7. PubMed ID: 20361897
[TBL] [Abstract][Full Text] [Related]
9. Amisulpride a selective dopamine antagonist and atypical antipsychotic: results of a meta-analysis of randomized controlled trials.
Leucht S
Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S15-20. PubMed ID: 14972080
[TBL] [Abstract][Full Text] [Related]
10. Sulpiride augmentation in people with schizophrenia partially responsive to clozapine. A double-blind, placebo-controlled study.
Shiloh R; Zemishlany Z; Aizenberg D; Radwan M; Schwartz B; Dorfman-Etrog P; Modai I; Khaikin M; Weizman A
Br J Psychiatry; 1997 Dec; 171():569-73. PubMed ID: 9519099
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of dopamine research in schizophrenia.
Pani L
Curr Med Res Opin; 2002; 18 Suppl 3():s3-7. PubMed ID: 12418605
[TBL] [Abstract][Full Text] [Related]
12. How do we choose between atypical antipsychotics? The advantages of amisulpride.
Mortimer AM
Int J Neuropsychopharmacol; 2004 Mar; 7 Suppl 1():S21-5. PubMed ID: 14972081
[TBL] [Abstract][Full Text] [Related]
13. Sulpiride: an antipsychotic with selective dopaminergic antagonist properties.
Caley CF; Weber SS
Ann Pharmacother; 1995 Feb; 29(2):152-60. PubMed ID: 7756714
[TBL] [Abstract][Full Text] [Related]
14. Extended-release paliperidone: efficacy, safety and tolerability profile of a new atypical antipsychotic.
Owen RT
Drugs Today (Barc); 2007 Apr; 43(4):249-58. PubMed ID: 17460786
[TBL] [Abstract][Full Text] [Related]
15. Consensus on the use of substituted benzamides in psychiatric patients.
Racagni G; Canonico PL; Ravizza L; Pani L; Amore M
Neuropsychobiology; 2004; 50(2):134-43. PubMed ID: 15292667
[TBL] [Abstract][Full Text] [Related]
16. Ziprasidone: a review of its use in schizophrenia and schizoaffective disorder.
Gunasekara NS; Spencer CM; Keating GM
Drugs; 2002; 62(8):1217-51. PubMed ID: 12010089
[TBL] [Abstract][Full Text] [Related]
17. Atypical antipsychotics: mechanism of action.
Seeman P
Can J Psychiatry; 2002 Feb; 47(1):27-38. PubMed ID: 11873706
[TBL] [Abstract][Full Text] [Related]
18. Is amisulpride an 'atypical' atypical antipsychotic agent?
Lecrubier Y
Int Clin Psychopharmacol; 2000 Dec; 15 Suppl 4():S21-6. PubMed ID: 11252520
[TBL] [Abstract][Full Text] [Related]
19. Amisulpride, an unusual "atypical" antipsychotic: a meta-analysis of randomized controlled trials.
Leucht S; Pitschel-Walz G; Engel RR; Kissling W
Am J Psychiatry; 2002 Feb; 159(2):180-90. PubMed ID: 11823257
[TBL] [Abstract][Full Text] [Related]
20. Is regionally selective D2/D3 dopamine occupancy sufficient for atypical antipsychotic effect? an in vivo quantitative [123I]epidepride SPET study of amisulpride-treated patients.
Bressan RA; Erlandsson K; Jones HM; Mulligan R; Flanagan RJ; Ell PJ; Pilowsky LS
Am J Psychiatry; 2003 Aug; 160(8):1413-20. PubMed ID: 12900302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
